Literature DB >> 3588890

[Nuclear magnetic resonance tomography of the sacroiliac joint. A new examination technic in the differential diagnosis of rheumatic diseases of the lumbosacral transition].

H Friedburg, S Meske, J Hennig, P Billmann, H H Peter, W Wenz.   

Abstract

25 patients with the clinical diagnoses of possible sacroiliitis were investigated by Magnetic Resonance Tomography (MR). Using axial or coronal tomography in a T1-weighted sequence (7 slices, 1 echo, NEX: 2, slice thickness 8 mm, TR: 600 ms, TE: 33 ms) and in a T2-weighted sequence (7 slices, 4 echos, NEX: 2, slice thickness 8 mm, TR: 1800 ms, TE: 33, 66, 99, 132 ms) we found normal sacroiliac joints in 10 patients, in 12 patients we diagnosed a sacroiliitis, in 3 patients a sacroiliac sclerosis. Descriptive evaluation and T2-calculation we showed, that MR is specific in differentiation of inflammation from sclerosis. The mean T2-relaxation time is 126 ms in healthy subjects, 320 ms in sacroiliitis and 87 ms in sclerotic areas. The results are significant in the Student-T-test (5% level). In addition the method allows the distinction of sclerosis from inflammation with a resolution of 2 mm. In evaluating sacroiliac rheumatic diseases MR may be helpful as a new imaging technique to complete the information of conventional radiography, computer assisted tomography and scintigraphy.

Entities:  

Mesh:

Year:  1987        PMID: 3588890

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

Review 1.  [Low-field magnetic resonance imaging : Just less expensive or completely different?]

Authors:  Jürgen Hennig
Journal:  Radiologe       Date:  2022-03-08       Impact factor: 0.635

Review 2.  [Grading sacroiliitis with emphasis on MRT-imaging].

Authors:  A G Jurik; N Egund
Journal:  Radiologe       Date:  2004-03       Impact factor: 0.635

Review 3.  A systematic critical review on MRI in spondyloarthritis.

Authors:  Bodil Arnbak; Charlotte Leboeuf-Yde; Tue Secher Jensen
Journal:  Arthritis Res Ther       Date:  2012-03-09       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.